Pharmaids Pharmaceuticals Ltd
Incorporated in 1989, Pharmaids Pharmaceuticals Ltd manufactures Bulk Drugs and Intermediaries.
- Market Cap ₹ 220 Cr.
- Current Price ₹ 62.2
- High / Low ₹ 87.5 / 31.9
- Stock P/E
- Book Value ₹ 16.8
- Dividend Yield 0.00 %
- ROCE -17.4 %
- ROE -16.3 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.74 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 5.22%
- Company has a low return on equity of -20.4% over last 3 years.
- Promoter holding has decreased over last 3 years: -30.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 4 | 0 | 15 | 19 | |
| 4 | 10 | 28 | 32 | |
| Operating Profit | 0 | -10 | -13 | -13 |
| OPM % | 3% | -87% | -66% | |
| 0 | 0 | 1 | 0 | |
| Interest | 0 | 0 | 2 | 2 |
| Depreciation | 0 | 0 | 2 | 2 |
| Profit before tax | 0 | -10 | -16 | -17 |
| Tax % | 0% | -24% | -24% | -22% |
| 0 | -8 | -12 | -14 | |
| EPS in Rs | 0.15 | -3.52 | -2.26 | -3.06 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 70% |
| TTM: | 29% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 64% |
| 3 Years: | 74% |
| 1 Year: | 10% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -20% |
| Last Year: | -16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 10 | 21 | 35 | 35 |
| Reserves | -2 | 1 | 37 | 24 |
| 0 | 0 | 9 | 39 | |
| 2 | 2 | 11 | 22 | |
| Total Liabilities | 11 | 25 | 91 | 120 |
| 0 | 0 | 63 | 77 | |
| CWIP | 0 | 2 | 7 | 5 |
| Investments | 0 | 3 | 0 | 0 |
| 11 | 19 | 21 | 39 | |
| Total Assets | 11 | 25 | 91 | 120 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -0 | -4 | -11 | -14 | |
| 0 | -5 | -75 | -12 | |
| 0 | 21 | 78 | 23 | |
| Net Cash Flow | 0 | 12 | -8 | -3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 124 | 65 | 59 | |
| Inventory Days | 91 | 0 | 114 | 359 |
| Days Payable | 236 | 163 | 480 | |
| Cash Conversion Cycle | -21 | 16 | -63 | |
| Working Capital Days | -18 | -9 | -50 | |
| ROCE % | -64% | -28% | -17% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
24 May - Copies of Newspaper publication of Audited Financial Results (Consolidated and standalone) for the quarter and year ended 31st March 2025.
-
Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31St, 2025
23 May - Audited standalone and consolidated financial results for FY ended March 31, 2025 approved and published.
- Submission Of Audited Financial Results Along With Auditors Report For The Quarter And Year Ended 31St March 2025 23 May
-
Board Meeting Intimation for Consideration And Approval Of Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended 31St March 2025.
20 May - Board meeting on May 23 to approve audited results; trading window closed till 48 hours post announcement.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
15 May - Annual Secretarial Compliance Report confirms Pharmaids' full regulatory compliance for FY ended March 31, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:
a) Specialty Chemicals:[1] Retinol, DL Alpha Tocopherol, D-Pantothenate, Cyanocobalamin, Pyridoxine Hcl, Thiamine, Nicotinic Acid, Water Sol. Vitamin E, Coenzyme Q10, D-Biotin
b) Skin Care:[2] Best care hands, Hands Sanitizer, Moisturizing Cream, Skin-Sure Plus, Skin-Sure Ultra, Alcohol Gel, Barrier Cream
c) Hospital Care:[3] Xepi Rub M, Facein Spray, Sod Hypochlorite, Sanmedin, Strumen-G, Strumen TRIACID, Facein Eco, Facein Power, Facein Spray, Sod Hypochlorite, Wipes, PPE
d) Generics:[4] Linzomust, Ceforoot 1.5g, Trendyclav-L, Cobasure Gold 2ML INJ, Benfoshine, Amplimmune, Thiaxa T8, Molprime SR, Citibrain-Plus, Duojoint